NICE shoots down Bayer's Stivarga in liver cancer, citing price, clinical questions
admin 8th November 2017 Uncategorised 0Bayer is working to position Stivarga as part of a treatment regimen for those in whom its first-line liver cancer fighter, Nexavar, has failed. But that’s not going to work in England. At least, not yet.
More: NICE shoots down Bayer's Stivarga in liver cancer, citing price, clinical questions
Source: fierce